TipRanks
Advertisement
Advertisement

DE:1RT Stock Latest News

Nuformix appoints Tim Metcalfe as new chairman to drive strategic value
Company AnnouncementsNuformix appoints Tim Metcalfe as new chairman to drive strategic value
27d ago
Nuformix Advances Inhaled Fibrosis Drug NXP002 With Positive Preclinical Data
PremiumCompany Announcements
Nuformix Advances Inhaled Fibrosis Drug NXP002 With Positive Preclinical Data
1M ago
Nuformix Secures Orphan Status and Funding to Advance Inhaled IPF Therapy
PremiumCompany Announcements
Nuformix Secures Orphan Status and Funding to Advance Inhaled IPF Therapy
4M ago
Nuformix updates market on enlarged share capital and voting rights
PremiumCompany Announcements
Nuformix updates market on enlarged share capital and voting rights
6M ago
Nuformix Raises £1m to Accelerate NXP002 Fibrosis Programme
PremiumCompany Announcements
Nuformix Raises £1m to Accelerate NXP002 Fibrosis Programme
6M ago
Nuformix Wins US Orphan Drug Status for IPF Candidate NXP002
PremiumCompany AnnouncementsNuformix Wins US Orphan Drug Status for IPF Candidate NXP002
6M ago
Nuformix Wins Strong Shareholder Backing as All AGM Resolutions Pass
Premium
Company Announcements
Nuformix Wins Strong Shareholder Backing as All AGM Resolutions Pass
7M ago
Nuformix Posts 2025 Annual Report and Sets Date for 2026 AGM
Premium
Company Announcements
Nuformix Posts 2025 Annual Report and Sets Date for 2026 AGM
8M ago
Nuformix Sharpens Focus on Partnering Lead IPF Drug NXP002 as Preclinical Data Strengthen Case
PremiumCompany Announcements
Nuformix Sharpens Focus on Partnering Lead IPF Drug NXP002 as Preclinical Data Strengthen Case
8M ago
Nuformix PLC Updates Total Voting Rights Following New Share Issuance
PremiumCompany Announcements
Nuformix PLC Updates Total Voting Rights Following New Share Issuance
10M ago
Nuformix Awaits FDA Response on Orphan Drug Designation for IPF Treatment
PremiumCompany Announcements
Nuformix Awaits FDA Response on Orphan Drug Designation for IPF Treatment
10M ago
Nuformix plc Successfully Completes Oversubscribed Open Offer
PremiumCompany Announcements
Nuformix plc Successfully Completes Oversubscribed Open Offer
10M ago
Nuformix Launches £228,081 Open Offer to Advance Drug Repurposing Initiatives
PremiumCompany AnnouncementsNuformix Launches £228,081 Open Offer to Advance Drug Repurposing Initiatives
11M ago
Nuformix Appoints New Auditor Amid Strategic Developments
Premium
Company Announcements
Nuformix Appoints New Auditor Amid Strategic Developments
12M ago
Nuformix to Present NXP002 Insights at European Respiratory Congress
Premium
Company Announcements
Nuformix to Present NXP002 Insights at European Respiratory Congress
12M ago
Nuformix Seeks US FDA Orphan Drug Designation for NXP002 in IPF
PremiumCompany Announcements
Nuformix Seeks US FDA Orphan Drug Designation for NXP002 in IPF
1y ago
Nuformix Confirms Total Voting Rights Following Share Issuance
PremiumCompany Announcements
Nuformix Confirms Total Voting Rights Following Share Issuance
1y ago
Nuformix Secures European Orphan Drug Designation for NXP002 in IPF
PremiumCompany Announcements
Nuformix Secures European Orphan Drug Designation for NXP002 in IPF
1y ago
Nuformix plc Announces Prospectus for New Share Issuance
PremiumCompany Announcements
Nuformix plc Announces Prospectus for New Share Issuance
1y ago
Nuformix Announces £210,000 Placing to Advance Fibrosis Treatment Program
PremiumCompany AnnouncementsNuformix Announces £210,000 Placing to Advance Fibrosis Treatment Program
1y ago
Nuformix Showcases Promising NXP002 Data at ATS Congress 2025
Premium
Company Announcements
Nuformix Showcases Promising NXP002 Data at ATS Congress 2025
1y ago
Nuformix Reports Progress on NXP002 and Financial Results for H1 2025
Premium
Company Announcements
Nuformix Reports Progress on NXP002 and Financial Results for H1 2025
1y ago

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >